Letters
American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: Comment on the article by Genovese et al
First published: 18 July 2011
No abstract is available for this article.
- 1
Genovese MC,
Kavanaugh A,
Weinblatt ME,
Peterfy C,
Dicarlo J,
White ML, et al.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis Rheum
2011;
63:
337–45.
- 2
Felson DT,
Anderson JJ,
Boers M,
Bombardier C,
Furst D,
Goldsmith C, et al.
American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.
Arthritis Rheum
1995;
38:
727–35.
- 3
American College of Rheumatology Committee to Reevaluate Improvement Criteria.
A proposed revision to the ACR20: the hybrid measure of the American College of Rheumatology response.
Arthritis Rheum
2007;
57:
193–202.
- 4
Van Vollenhoven RF,
Felson D,
Strand V,
Weinblatt ME,
Luijtens K,
Keystone EC.
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
Arthritis Care Res (Hoboken)
2011;
63:
128–34.
